ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation.

Angiotensin receptor blockers Angiotensin-converting enzyme inhibitors Cardiovascular outcomes Heart failure Hypertension Myocardial infarction Renin–angiotensin–aldosterone system Stroke

Journal

Cardiology and therapy

ISSN: 2193-8261

Titre abrégé: Cardiol Ther

Pays: England

ID NLM: 101634495

Informations de publication

Date de publication:
25 Oct 2024

Historique:

received: 10 06 2024

accepted: 23 08 2024

medline: 26 10 2024

pubmed: 26 10 2024

entrez: 25 10 2024

Statut: aheadofprint

Résumé

The renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in regulating blood pressure (BP), with dysregulation of RAAS resulting in hypertension and potentially heart failure (HF), myocardial infarction (MI), cardio-renal syndrome, and stroke. RAAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs), have advantages beyond BP control. However, differences between these two drug classes need to be considered when choosing a therapy for preventing cardiovascular events. A panel of 36 Egyptian cardiologists developed consensus statements on RAAS inhibitors for primary and secondary prevention of cardiovascular outcomes and stroke, using a modified three-step Delphi process. The consensus statements highlight the importance of effective BP control and the role of RAAS blockade for prevention and management of various cardiovascular diseases. ACEis and ARBs differ in their mode of action and, thus, clinical effects. On the basis of available evidence, the consensus group recommended the following: ACEis should be considered as first choice (in preference to ARBs) to reduce the risk of MI, for primary prevention of HF, and for secondary prevention of stroke. ACEis and ARBs show equivalent efficacy for the primary prevention of stroke. Evidence also favors the preferential use of ACEis in patients with type 2 diabetes, for BP control, for the primary prevention of diabetic kidney disease, and to reduce the risk of major cardiovascular and renal outcomes. Treatment with an ACEi should be started within 24 h of ST segment elevation MI (and continued long term) in patients with HF, left ventricular systolic dysfunction, and/or diabetes. Angiotensin receptor/neprilysin inhibitors (ARNIs) are the first choice for patients with HF and reduced ejection fraction, with ACEis being the second choice in this group. ARBs are indicated as alternatives in patients who cannot tolerate ACEis. ACEis may be associated with cough development, but the incidence tends to be overestimated, and the risk can be reduced by use of a lipophilic ACEi or combining the ACEi with a calcium channel blocker. RAAS blockade is an essential component of hypertension therapy; however, the protective effects provided by ACEis are superior to those of ARBs. Therefore, an ACEi is indicated in almost all cases, unless not tolerated. Overstimulation of the renin–angiotensin–aldosterone system—a key regulator of blood pressure, and fluid and electrolyte balance—is known to cause an increase in blood pressure (also known as “hypertension”) and other diseases of the heart and blood vessels (the cardiovascular system). As such, treatments to block (or inhibit) this overstimulation are an essential part of medical strategies designed for the prevention of cardiovascular disease, especially in patients with hypertension (in whom the risk of death due to cardiovascular causes is high). Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are two types of medication that block overstimulation of the renin–angiotensin–aldosterone system, but they work in different ways. Angiotensin-converting enzyme inhibitors are superior to angiotensin receptor blockers after heart attacks (acute myocardial infarction), in patients with heart failure, for the prevention of stroke in individuals who have already had a stroke, and in patients with diabetes. Both types of medication have beneficial effects on the kidneys and associated outcomes, but only angiotensin-converting enzyme inhibitors have been shown to significantly reduce death due to cardiovascular causes, as well as death due to any cause. Overall, the protective effects of angiotensin-converting enzyme inhibitors on the heart are substantially greater than those of angiotensin receptor blockers, meaning that treatment with an angiotensin-converting enzyme inhibitor is preferred in all patients, except those who cannot tolerate the side effects of this drug class.

Autres résumés

Type: plain-language-summary (eng)

Overstimulation of the renin–angiotensin–aldosterone system—a key regulator of blood pressure, and fluid and electrolyte balance—is known to cause an increase in blood pressure (also known as “hypertension”) and other diseases of the heart and blood vessels (the cardiovascular system). As such, treatments to block (or inhibit) this overstimulation are an essential part of medical strategies designed for the prevention of cardiovascular disease, especially in patients with hypertension (in whom the risk of death due to cardiovascular causes is high). Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are two types of medication that block overstimulation of the renin–angiotensin–aldosterone system, but they work in different ways. Angiotensin-converting enzyme inhibitors are superior to angiotensin receptor blockers after heart attacks (acute myocardial infarction), in patients with heart failure, for the prevention of stroke in individuals who have already had a stroke, and in patients with diabetes. Both types of medication have beneficial effects on the kidneys and associated outcomes, but only angiotensin-converting enzyme inhibitors have been shown to significantly reduce death due to cardiovascular causes, as well as death due to any cause. Overall, the protective effects of angiotensin-converting enzyme inhibitors on the heart are substantially greater than those of angiotensin receptor blockers, meaning that treatment with an angiotensin-converting enzyme inhibitor is preferred in all patients, except those who cannot tolerate the side effects of this drug class.

Identifiants

DOI: 10.1007/s40119-024-00381-6 PMID: 39455534

pubmed: 39455534

doi: 10.1007/s40119-024-00381-6

pii: 10.1007/s40119-024-00381-6

doi:

Types de publication

Journal Article

Langues

eng

Informations de copyright

Références

World Health Organization. Global report on hypertension: the race against a silent killer. 2023. WHO, Geneva, Switzerland. https://www.who.int/publications/i/item/9789240081062 . Accessed Aug 13, 2024.

Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16:223–37.

pubmed: 32024986 pmcid: 7998524 doi: 10.1038/s41581-019-0244-2

Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874–2071.

pubmed: 37345492 doi: 10.1097/HJH.0000000000003480

Chen R, Suchard MA, Krumholz HM, et al. Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension. 2021;78:591–603.

pubmed: 34304580 doi: 10.1161/HYPERTENSIONAHA.120.16667

Unger T, Borghi C, Charchar F, et al. 2020 International society of hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334–57.

pubmed: 32370572 doi: 10.1161/HYPERTENSIONAHA.120.15026

Jaiswal N, Field R. Network meta-analysis: the way forward for evidence-based decisions. Clin Epidemiol Glob Health. 2024;26: 101531.

doi: 10.1016/j.cegh.2024.101531

Broder MS, Gibbs SN, Yermilov I. An adaptation of the RAND/UCLA modified Delphi panel method in the time of COVID-19. J Healthc Leadersh. 2022;14:63–70.

pubmed: 35634010 pmcid: 9130741 doi: 10.2147/JHL.S352500

Clarke NE, Turner AJ. Angiotensin-converting enzyme 2: the first decade. Int J Hypertens. 2012;2012: 307315.

pubmed: 22121476 doi: 10.1155/2012/307315

Chalmers JP, Wing LM, West MJ, et al. Effects of enalapril and hydrochlorothiazide on blood pressure, renin-angiotensin system, and atrial natriuretic factor in essential hypertension: a double blind factorial cross-over study. Aust N Z J Med. 1986;16:475–80.

pubmed: 3026294 doi: 10.1111/j.1445-5994.1986.tb02014.x

Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605–10.

pubmed: 15897343 doi: 10.1161/CIRCULATIONAHA.104.510461

Gavras I, Gavras H. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin. 1999;15:15–24.

pubmed: 10216807 doi: 10.1185/03007999909115169

Grossman E, Peleg E, Carroll J, Shamiss A, Rosenthal T. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens. 1994;7:1041–4.

pubmed: 7702796 doi: 10.1093/ajh/7.12.1041

Nakamura T, Kawachi K, Saito Y, et al. Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension. Int Heart J. 2009;50:501–12.

pubmed: 19609054 doi: 10.1536/ihj.50.501

Arendse LB, Danser AHJ, Poglitsch M, et al. Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure. Pharmacol Rev. 2019;71:539–70.

pubmed: 31537750 pmcid: 6782023 doi: 10.1124/pr.118.017129

Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res. 2007;73:237–46.

pubmed: 17140552 doi: 10.1016/j.cardiores.2006.10.021

Ancion A, Tridetti J, Nguyen Trung ML, Oury C, Lancellotti P. A review of the role of bradykinin and nitric oxide in the cardioprotective action of angiotensin-converting enzyme inhibitors: focus on perindopril. Cardiol Ther. 2019;8:179–91.

pubmed: 31578675 pmcid: 6828891 doi: 10.1007/s40119-019-00150-w

Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation. 1998;97:2222–9.

pubmed: 9631871 doi: 10.1161/01.CIR.97.22.2222

Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension. 2003;41:1281–6.

pubmed: 12719441 doi: 10.1161/01.HYP.0000070956.57418.22

Cangiano E, Marchesini J, Campo G, et al. ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes. Am J Cardiovasc Drugs. 2011;11:189–98.

pubmed: 21619382 doi: 10.2165/11589400-000000000-00000

Fogari R, Zoppi A. Antihypertensive drugs and fibrinolytic function. Am J Hypertens. 2006;19:1293–9.

pubmed: 17161777 doi: 10.1016/j.amjhyper.2006.04.013

Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension. 1999;34:285–90.

pubmed: 10454455 doi: 10.1161/01.HYP.34.2.285

Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2008;2008: CD003823.

pubmed: 18843651 pmcid: 7156914

Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2008;2008: CD003822.

pubmed: 18843650 pmcid: 6669255

Peresuodei TS, Gill A, Orji C, Reghefaoui M, Saavedra Palacios MS, Nath TS. A comparative study of the safety and efficacy between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the management of hypertension: a systematic review. Cureus. 2024;16: e54311.

pubmed: 38496070 pmcid: 10944326

Sobhy M, Saleh M, Hamid MA. 2A.05: efficacy of combination perindopril/amlodipine with or without diuretics in Egyptian patients with uncontrolled hypertension: the CONTROL study. J Hypertens. 2015;33: e20.

doi: 10.1097/01.hjh.0000467403.71537.41

Messerli FH, Hofstetter L, Rimoldi SF, Rexhaj E, Bangalore S. Risk factor variability and cardiovascular outcome: JACC review topic of the week. J Am Coll Cardiol. 2019;73:2596–603.

pubmed: 31118154 doi: 10.1016/j.jacc.2019.02.063

Wan EYF, Yu EYT, Chin WY, Fong DYT, Choi EPH, Lam CLK. Association of visit-to-visit variability of systolic blood pressure with cardiovascular disease, chronic kidney disease and mortality in patients with hypertension. J Hypertens. 2020;38:943–53.

pubmed: 31904623 doi: 10.1097/HJH.0000000000002347

Dasa O, Smith SM, Howard G, et al. Association of 1-Year blood pressure variability with long-term mortality among adults with coronary artery disease: a post hoc analysis of a randomized clinical trial. JAMA Netw Open. 2021;4: e218418.

pubmed: 33914047 pmcid: 8085725 doi: 10.1001/jamanetworkopen.2021.8418

Rothwell PM, Howard SC, Dolan E, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9:469–80.

pubmed: 20227347 doi: 10.1016/S1474-4422(10)70066-1

Asmar RG, London GM, O’Rourke ME, Safar ME. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension. 2001;38:922–6.

pubmed: 11641310 doi: 10.1161/hy1001.095774

Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213–25.

pubmed: 16476843 doi: 10.1161/CIRCULATIONAHA.105.595496

Boutouyrie P, Achouba A, Trunet P, Laurent S. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension. 2010;55:1314–22.

pubmed: 20404219 doi: 10.1161/HYPERTENSIONAHA.109.148999

Neutel JM. Effect of the renin–angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J Hum Hypertens. 2004;18:599–606.

pubmed: 15190263 doi: 10.1038/sj.jhh.1001714

Dézsi CA, Szentes V. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on prothrombotic processes and myocardial infarction risk. Am J Cardiovasc Drugs. 2016;16:399–406.

pubmed: 27580998 pmcid: 5126203 doi: 10.1007/s40256-016-0185-0

Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–31.

pubmed: 15207952 doi: 10.1016/S0140-6736(04)16451-9

Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772–6.

pubmed: 13678870 doi: 10.1016/S0140-6736(03)14284-5

Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875–86.

pubmed: 12714861 doi: 10.1097/00004872-200305000-00011

Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174–83.

pubmed: 18757085 doi: 10.1016/S0140-6736(08)61242-8

Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225–37.

pubmed: 18753639 pmcid: 2714258 doi: 10.1056/NEJMoa0804593

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–53.

pubmed: 10639539 doi: 10.1056/NEJM200001203420301

Ferrari R, Fox K. Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate “EUROPA” story. Drugs. 2009;69:265–77.

pubmed: 19275271 doi: 10.2165/00003495-200969030-00003

PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J. 2003;24:475–84.

doi: 10.1016/S0195-668X(02)00804-7

Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895–906.

pubmed: 16154016 doi: 10.1016/S0140-6736(05)67185-1

Bangalore S, Fakheri R, Toklu B, Ogedegbe G, Weintraub H, Messerli FH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials. Mayo Clin Proc. 2016;91:51–60.

pubmed: 26763511 doi: 10.1016/j.mayocp.2015.10.019

Savarese G, Costanzo P, Cleland JG, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol. 2013;61:131–42.

pubmed: 23219304 doi: 10.1016/j.jacc.2012.10.011

Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006;114:838–54.

pubmed: 16923768 doi: 10.1161/CIRCULATIONAHA.105.594986

Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13–115.

pubmed: 29133356

Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104.

pubmed: 30165516 doi: 10.1093/eurheartj/ehy339

Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59.

pubmed: 18378520 doi: 10.1056/NEJMoa0801317

Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–619.

pubmed: 22922416 doi: 10.1093/eurheartj/ehs215

O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:529–55.

pubmed: 23247303 doi: 10.1161/CIR.0b013e3182742c84

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs–overview and meta-analyses. J Hypertens. 2015;33:195–211.

pubmed: 25485720 doi: 10.1097/HJH.0000000000000447

Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–8.

pubmed: 13678872 doi: 10.1016/S0140-6736(03)14286-9

Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.

pubmed: 11937178 doi: 10.1016/S0140-6736(02)08089-3

Mancia G, Parati G, Bilo G, et al. Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). Hypertension. 2012;60:1400–6.

pubmed: 23071122 doi: 10.1161/HYPERTENSIONAHA.112.199562

Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895–1032.

pubmed: 35363499

Lin Q, Ye T, Ye P, et al. Hypertension in stroke survivors and associations with national premature stroke mortality: data for 2·5 million participants from multinational screening campaigns. Lancet Glob Health. 2022;10:e1141–9.

pubmed: 35839813 doi: 10.1016/S2214-109X(22)00238-8

Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338: b1665.

pubmed: 19454737 pmcid: 2684577 doi: 10.1136/bmj.b1665

Wright JW, Harding JW. The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases. Pflugers Arch. 2013;465:133–51.

pubmed: 22535332 doi: 10.1007/s00424-012-1102-2

Chrysant SG. The pathophysiologic role of the brain renin-angiotensin system in stroke protection: clinical implications. J Clin Hypertens (Greenwich). 2007;9:454–9.

pubmed: 17541331 doi: 10.1111/j.1524-6175.2007.06602.x

Chrysant SG. The role of angiotensin II receptors in stroke protection. Curr Hypertens Rep. 2012;14:202–8.

pubmed: 22447068 doi: 10.1007/s11906-012-0257-8

Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002;324:699–702.

pubmed: 11909785 pmcid: 99052 doi: 10.1136/bmj.324.7339.699

Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.

pubmed: 18378519 doi: 10.1056/NEJMoa0801369

Kizer JR, Dahlöf B, Kjeldsen SE, et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension. 2005;45:46–52.

pubmed: 15583076 doi: 10.1161/01.HYP.0000151324.05355.1c

Ricci F, Di Castelnuovo A, Savarese G, Perrone Filardi P, De Caterina R. ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - a network meta-analysis. Int J Cardiol. 2016;217:128–34.

pubmed: 27179902 doi: 10.1016/j.ijcard.2016.04.132

PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–41.

doi: 10.1016/S0140-6736(01)06178-5

Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52:e364–467.

pubmed: 34024117 doi: 10.1161/STR.0000000000000375

Collaboration BPLTT. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397:1625–36.

doi: 10.1016/S0140-6736(21)00590-0

van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33:2088–97.

pubmed: 22511654 pmcid: 3418510 doi: 10.1093/eurheartj/ehs075

Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014;174:773–85.

pubmed: 24687000 doi: 10.1001/jamainternmed.2014.348

Kostis JB. Angiotensin-converting enzyme inhibitors. Emerging differences and new compounds. Am J Hypertens. 1989;2:57–64.

pubmed: 2643970 doi: 10.1093/ajh/2.1.57

Gohlke P, Urbach H, Schölkens B, Unger T. Inhibition of converting enzyme in the cerebrospinal fluid of rats after oral treatment with converting enzyme inhibitors. J Pharmacol Exp Ther. 1989;249:609–16.

pubmed: 2542535

Tsimihodimos V, Gonzalez-Villalpando C, Meigs JB, Ferrannini E. Hypertension and diabetes mellitus: coprediction and time trajectories. Hypertension. 2018;71:422–8.

pubmed: 29335249 doi: 10.1161/HYPERTENSIONAHA.117.10546

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.

pubmed: 15111519 doi: 10.2337/diacare.27.5.1047

Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23.

pubmed: 15652604 doi: 10.1016/S0140-6736(05)17741-1

Chung HH, Won KC. Prevalence, awareness, and control of hypertension among diabetic Koreans. Diabetes Metab J. 2011;35:337–9.

pubmed: 21977452 pmcid: 3178693 doi: 10.4093/dmj.2011.35.4.337

Abdissa D, Kene K. Prevalence and determinants of hypertension among diabetic patients in Jimma University Medical Center, Southwest Ethiopia, 2019. Diabetes Metab Syndr Obes. 2020;13:2317–25.

pubmed: 32669865 pmcid: 7335849 doi: 10.2147/DMSO.S255695

Vargas-Uricoechea H, Cáceres-Acosta MF. Control of blood pressure and cardiovascular outcomes in type 2 diabetes. Open Med (Wars). 2018;13:304–23.

pubmed: 30140748 doi: 10.1515/med-2018-0048

Thiruvoipati T, Kielhorn CE, Armstrong EJ. Peripheral artery disease in patients with diabetes: epidemiology, mechanisms, and outcomes. World J Diabetes. 2015;6:961–9.

pubmed: 26185603 pmcid: 4499529 doi: 10.4239/wjd.v6.i7.961

Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992;19:403–18.

pubmed: 1568757 doi: 10.1161/01.HYP.19.5.403

Weidmann P, Boehlen LM, de Courten M. Pathogenesis and treatment of hypertension associated with diabetes mellitus. Am Heart J. 1993;125:1498–513.

pubmed: 8480621 doi: 10.1016/0002-8703(93)90447-H

Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122:481–6.

pubmed: 7872581 doi: 10.7326/0003-4819-122-7-199504010-00001

Huang Z, Willett WC, Manson JE, et al. Body weight, weight change, and risk for hypertension in women. Ann Intern Med. 1998;128:81–8.

pubmed: 9441586 doi: 10.7326/0003-4819-128-2-199801150-00001

DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–94.

pubmed: 2044434 doi: 10.2337/diacare.14.3.173

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703–13.

pmcid: 28659 doi: 10.1136/bmj.317.7160.703

Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313:603–15.

pubmed: 25668264 doi: 10.1001/jama.2014.18574

Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–40.

pubmed: 17765963 doi: 10.1016/S0140-6736(07)61303-8

Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371:1392–406.

pubmed: 25234206 doi: 10.1056/NEJMoa1407963

Haller H, Ito S, Izzo JL Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907–17.

pubmed: 21388309 doi: 10.1056/NEJMoa1007994

Marx N, Federici M, Schutt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44:4043–140.

pubmed: 37622663 doi: 10.1093/eurheartj/ehad192

International Diabetes Federation. IDF clinical practice recommendations for managing type 2 diabetes in primary care. 2017. https://idf.org/media/uploads/2023/05/attachments-63.pdf . Accessed Aug 12, 2024.

American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of care in diabetes-2024. Diabetes Care. 2024;47:S179–218.

doi: 10.2337/dc24-S010

Pugh D, Gallacher PJ, Dhaun N. Management of hypertension in chronic kidney disease. Drugs. 2019;79:365–79.

pubmed: 30758803 pmcid: 6422950 doi: 10.1007/s40265-019-1064-1

Thomas B, Matsushita K, Abate KH, et al. Global cardiovascular and renal outcomes of reduced GFR. J Am Soc Nephrol. 2017;28:2167–79.

pubmed: 28408440 pmcid: 5491277 doi: 10.1681/ASN.2016050562

Heerspink HJ. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway. Adv Chronic Kidney Dis. 2011;18:290–9.

pubmed: 21782135 doi: 10.1053/j.ackd.2011.04.001

Xu R, Sun S, Huo Y, et al. Effects of ACEIs versus ARBs on proteinuria or albuminuria in primary hypertension: a meta-analysis of randomized trials. Medicine. 2015;94: e1560.

pubmed: 26426627 pmcid: 4616860 doi: 10.1097/MD.0000000000001560

Lv J, Perkovic V, Foote CV, Craig ME, Craig JC, Strippoli GF. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev. 2012;12: CD004136.

pubmed: 23235603

García-Donaire JA, Segura J, Cerezo C, Ruilope LM. A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients. Blood Press. 2011;20:322–34.

pubmed: 21936729 doi: 10.3109/08037051.2011.602878

Xie X, Liu Y, Perkovic V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67:728–41.

pubmed: 26597926 doi: 10.1053/j.ajkd.2015.10.011

Zhang Y, He D, Zhang W, et al. ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3–5: a network meta-analysis of randomised clinical trials. Drugs. 2020;80:797–811.

pubmed: 32333236 pmcid: 7242277 doi: 10.1007/s40265-020-01290-3

Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO. Clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;2021(99):S1–87.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;2024(105):S117–314.

Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720–826.

pubmed: 37622654 doi: 10.1093/eurheartj/ehad191

Yousef ZR, Redwood SR, Marber MS. Postinfarction left ventricular remodelling: where are the theories and trials leading us? Heart. 2000;83:76–80.

pubmed: 10618340 pmcid: 1729255 doi: 10.1136/heart.83.1.76

Brown NJ, Abbas A, Byrne D, Schoenhard JA, Vaughan DE. Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women. Circulation. 2002;105:304–9.

pubmed: 11804984 doi: 10.1161/hc0302.102570

Soejima H, Ogawa H, Yasue H, et al. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. J Am Coll Cardiol. 1999;34:983–8.

pubmed: 10520779 doi: 10.1016/S0735-1097(99)00318-6

Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J. 2006;27:512–8.

pubmed: 16311236 doi: 10.1093/eurheartj/ehi668

Hikosaka M, Yuasa F, Yuyama R, et al. Effect of angiotensin-converting enzyme inhibitor on cardiopulmonary baroreflex sensitivity in patients with acute myocardial infarction. Am J Cardiol. 2000;86:1241-4, A6.

pubmed: 11090798

Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med. 1988;319:80–6.

pubmed: 2967917 doi: 10.1056/NEJM198807143190204

Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol. 1999;33:598–604.

pubmed: 10080457 doi: 10.1016/S0735-1097(98)00609-3

Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355:1575–81.

pubmed: 10821360 doi: 10.1016/S0140-6736(00)02212-1

Latini R, Tognoni G, Maggioni AP, et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. J Am Coll Cardiol. 2000;35:1801–7.

pubmed: 10841227 doi: 10.1016/S0735-1097(00)00638-0

Rodrigues EJ, Eisenberg MJ, Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med. 2003;115:473–9.

pubmed: 14563504 doi: 10.1016/S0002-9343(03)00435-2

Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752–60.

pubmed: 12241832 doi: 10.1016/S0140-6736(02)09895-1

Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–906.

pubmed: 14610160 doi: 10.1056/NEJMoa032292

Kim KH, Choi BG, Rha SW, Choi CU, Jeong MH. Impact of renin angiotensin system inhibitor on 3-year clinical outcomes in acute myocardial infarction patients with preserved left ventricular systolic function: a prospective cohort study from Korea Acute Myocardial Infarction Registry (KAMIR). BMC Cardiovasc Disord. 2021;21:251.

pubmed: 34020593 pmcid: 8140424 doi: 10.1186/s12872-021-02070-x

Lee JG, Joo SJ, Kim SY, et al. Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction. PLoS One. 2023;18: e0281460.

pubmed: 36893150 pmcid: 9997890 doi: 10.1371/journal.pone.0281460

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726.

pubmed: 34447992 doi: 10.1093/eurheartj/ehab368

Ezekowitz JA, O’Meara E, McDonald MA, et al. 2017 comprehensive update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol. 2017;33:1342–433.

pubmed: 29111106 doi: 10.1016/j.cjca.2017.08.022

Strauss MH, Hall AS. Angiotensin receptor blockers do not reduce risk of myocardial infarction, cardiovascular death, or total mortality: further evidence for the ARB-MI paradox. Circulation. 2017;135:2088–90.

pubmed: 28559493 doi: 10.1161/CIRCULATIONAHA.117.026112

Burnett H, Earley A, Voors AA, et al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circ Heart Fail. 2017;10: e003529.

pubmed: 28087688 pmcid: 5265698 doi: 10.1161/CIRCHEARTFAILURE.116.003529

Levy BI. How to explain the differences between renin angiotensin system modulators. Am J Hypertens. 2005;18:134s-s141.

pubmed: 16125050 doi: 10.1016/j.amjhyper.2005.05.005

Lévy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation. 2004;109:8–13.

pubmed: 14707017 doi: 10.1161/01.CIR.0000096609.73772.C5

McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44:3627–39.

pubmed: 37622666 doi: 10.1093/eurheartj/ehad195

Dinicolantonio JJ, Lavie CJ, O’Keefe JH. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril. Postgrad Med. 2013;125:154–68.

pubmed: 23933903 doi: 10.3810/pgm.2013.07.2687

Vedantam V, Magacha HM, Vedantam N, Dahya V, Abu-Heija U. A case report of losartan induced angioedema. Cureus. 2023;15: e36525.

pubmed: 37090415 pmcid: 10120880

Latini R, Masson S, Anand I, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2002;106:2454–8.

pubmed: 12417542 doi: 10.1161/01.CIR.0000036747.68104.AC

Brugts JJ, Arima H, Remme W, et al. The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease. Int J Cardiol. 2014;176:718–23.

pubmed: 25189490 doi: 10.1016/j.ijcard.2014.07.108

Taddei S, Bortolotto L. Unraveling the pivotal role of bradykinin in ACE inhibitor activity. Am J Cardiovasc Drugs. 2016;16:309–21.

pubmed: 27260014 doi: 10.1007/s40256-016-0173-4

Fogari R, Zoppi A, Mugellini A, Preti P, Banderali A, Salvetti A. Effects of amlodipine, nifedipine GITS, and indomethacin on angiotensin-converting enzyme inhibitor-induced cough: a randomized, placebo-controlled, double-masked, crossover study. Curr Ther Res. 1999;60:121–8.

doi: 10.1016/S0011-393X(00)88520-3

Brown T, Gonzalez J, Monteleone C. Angiotensin-converting enzyme inhibitor-induced angioedema: a review of the literature. J Clin Hypertens (Greenwich). 2017;19:1377–82.

pubmed: 28994183 doi: 10.1111/jch.13097

Borghi C, Cicero AF, Agnoletti D, Fiorini G. Pathophysiology of cough with angiotensin-converting enzyme inhibitors: How to explain within-class differences? Eur J Intern Med. 2023;110:10–5.

pubmed: 36628825 doi: 10.1016/j.ejim.2023.01.005

Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28:1042–50.

pubmed: 17074919 doi: 10.1183/09031936.00074905

Vukadinović D, Vukadinović AN, Lavall D, Laufs U, Wagenpfeil S, Böhm M. Rate of cough during treatment with angiotensin-converting enzyme inhibitors: a meta-analysis of randomized placebo-controlled trials. Clin Pharmacol Ther. 2019;105:652–60.

pubmed: 29330882 doi: 10.1002/cpt.1018

Sato A, Fukuda S. A prospective study of frequency and characteristics of cough during ACE inhibitor treatment. Clin Exp Hypertens. 2015;37:563–8.

pubmed: 25992489 doi: 10.3109/10641963.2015.1026040

Momoniat T, Ilyas D, Bhandari S. ACE inhibitors and ARBs: managing potassium and renal function. Cleve Clin J Med. 2019;86:601–7.

pubmed: 31498767 doi: 10.3949/ccjm.86a.18024

Schmidt M, Mansfield KE, Bhaskaran K, et al. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. BMJ. 2017;356: j791.

pubmed: 28279964 pmcid: 5421447 doi: 10.1136/bmj.j791

Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.

pubmed: 11565517 doi: 10.1056/NEJMoa011303

Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.

pubmed: 11565518 doi: 10.1056/NEJMoa011161

Bilous R, Chaturvedi N, Sjølie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med. 2009;151:11–20.

pubmed: 19451554 doi: 10.7326/0003-4819-151-1-200907070-00120

Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–28.

pubmed: 19052124 doi: 10.1056/NEJMoa0806182

ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.

doi: 10.1056/NEJMoa1001286